Optimi Health is advancing a 6% psilocybin extract for the treatment of treatment-resistant depression, representing an ongoing development in psychedelic pharmacotherapy.
Optimi Health reports advancement in the production of high-purity natural psilocybin extract, a key development for the manufacturing and standardization of psilocybin-based psychedelic therapies.
Research investigating optimal dosing levels for ADHD medications provides clinical guidance for prescribing psychiatrists seeking to maximize efficacy and minimize side effects.
ASCP consensus recommendations provide guidance on the timing and methods for deprescribing stimulants in ADHD care, addressing a key prescribing decision for psychiatrists.
This article reviews the comparative efficacy, pharmacokinetics, and clinical strategies for using lorazepam versus diazepam in managing alcohol withdrawal, highlighting that while both are effective, lorazepam may be preferred for cost and safety in specific populations.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Oct 03 – May 26)
- Prescribe z-drugs or DORAs as first-line agents for primary insomnia to minimize the risk of tolerance associated with benzodiazepines.
- Reserve inpatient benzodiazepine tapering for clinical stabilization rather than complete discontinuation, acknowledging that insurance barriers often complicate safe outpatient deprescribing.
- Consider lorazepam over diazepam for alcohol withdrawal in patients with hepatic impairment or when cost-effectiveness is a priority, as both are effective but lorazepam offers specific safety and logistical advantages.
- Counsel male patients of reproductive age that ADHD stimulant use may be associated with reduced semen volume, a potential reproductive side effect to monitor.
- Reassure patients undergoing rTMS that treatment-emergent headaches, while associated with younger age, female sex, and higher baseline severity, do not negatively impact clinical response or treatment retention.
- Utilize ASCP consensus recommendations to guide the timing and methods of stimulant deprescribing in ADHD care to ensure safe transitions.
- Monitor for somnolence and gastrointestinal effects as the primary manageable adverse events when prescribing pharmaceutical-grade CBD for developmental and epileptic encephalopathies.
- Recognize that while psilocybin shows promise for treatment-resistant depression and PTSD, current evidence is largely driven by early-phase trials and preclinical mechanistic insights rather than large-scale confirmatory data.
- Understand that preclinical animal models have significant translational challenges in predicting the efficacy of psychedelic drugs as fast-acting antidepressants, requiring cautious interpretation of non-human data.
Drug Development 3
Red Light Holland expands its partnership with Allu Therapeutics to distribute Filament Health's GMP-compliant botanical psilocybin candidate PEX010 in New Zealand.
Phase 1 trial data for GM-2505, a novel psychedelic 5-HT2A receptor agonist, detailing its pharmacokinetic, safety, and pharmacodynamic profiles in healthy volunteers.
This article critically appraises the validity of preclinical animal models in predicting the efficacy of psychedelic drugs as fast-acting antidepressants, highlighting translational challenges in psychopharmacology.
Diagnosis & Treatment 2
This opinion piece critiques ASAM's benzodiazepine tapering guidelines, clarifying that inpatient care is primarily for stabilization rather than complete discontinuation and highlighting insurance barriers that complicate safe deprescribing.
A Swedish study suggests psilocybin may provide rapid relief for depression symptoms, highlighting potential therapeutic applications for this psychedelic compound.
Clinical Pearl 4
A clinical trial is recruiting patients taking specific antipsychotics (olanzapine, quetiapine, risperidone, clozapine) to evaluate the efficacy of a probiotic formula compared to placebo.
This practical guide outlines prescribing principles for sedative-hypnotics, emphasizing the selection of z-drugs or DORAs for primary insomnia versus off-label agents for secondary insomnia, while highlighting risks of tolerance with benzodiazepines.
A retrospective study of 938 rTMS patients found that treatment-emergent headaches are associated with younger age, female sex, and higher baseline depression severity, but do not negatively impact clinical response or retention.
A nonrandomized open-label trial investigates the safety and tolerability of single-dose psilocybin for PTSD, contributing to the early-stage clinical evaluation of this psychedelic agent for a major psychiatric indication.
Mechanism of Action 5
This pilot study identifies psilocybin-induced DNA methylation changes in genes related to neuroplasticity and immune function in patients with alcohol use disorder, offering mechanistic insights into its potential therapeutic effects despite failing to meet primary clinical endpoints.
Preclinical research demonstrates that psilocybin modulates social behavior in mice in a time-dependent manner, providing mechanistic insights into the potential therapeutic effects of psychedelics on social deficits.
Preclinical study demonstrating that psilocybin modulates social behavior in mice in a time-dependent manner, providing mechanistic insight into its potential effects on social cognition relevant to psychiatric conditions.
Preclinical study in mice elucidates the relationship between psilocybin's behavioral effects, 5-HT2A receptor occupancy, and neuroplastic changes, providing mechanistic insight into its antidepressant potential.
This article discusses the mechanisms of psilocybin for treating PTSD, a topic within the scope of psychiatric pharmacology and novel therapeutic agents.
Journal Article 3
A meta-analysis of 46 studies confirms pharmaceutical-grade CBD provides clinically meaningful seizure reduction in approximately half of patients with developmental and epileptic encephalopathies, with a manageable safety profile dominated by somnolence and GI effects.
A systematic review and network meta-analysis evaluates the efficacy of psychedelics for managing psychological and existential distress in terminally ill patients, providing evidence for their use in palliative care settings.
An updated systematic review and meta-analysis evaluates the efficacy of psilocybin for major depressive disorder, providing evidence on this psychedelic intervention for treatment-resistant depression.
Substance Use 1
A systematic review evaluates the impact of psychedelics on craving in substance use disorders, contributing to the evidence base for psychedelic-assisted therapy in addiction treatment.